Contact information
james.griffiths@psych.ox.ac.uk
pax-d@psych.ox.ac.uk
+44 (0)1865 618 160
James Griffiths
Clinical Trials Manager
My role as part of the Oxford Brain Health Clinical Trials Unit is to support the set-up and delivery of clinical trials. Currently I am managing the NIHR EME funded PAX-D trial in treatment resistant depression, led by Dr Michael Browning.
Prior to joining the OBHCTU and the Department of Psychiatry in 2019, I worked on a variety of clinical trials in paediatric and adult haemato-oncology, neonatal intensive care and acute brain injury in the NHS, at the University of Oxford's NPEU CTU and then the CR UK & UCL Cancer Trials Centre, as a Trial Manager and then Senior Trial Manager.
Recent publications
-
Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial.
Journal article
ELFIN trial investigators group None., (2019), Lancet, 393, 423 - 433
-
Enteral lactoferrin to prevent infection for very preterm infants: the ELFIN RCT.
Journal article
Griffiths J. et al, (2018), Health Technol Assess, 22, 1 - 60
-
Summary Protocol for a Multi-Centre Randomised Controlled Trial of Enteral Lactoferrin Supplementation in Newborn Very Preterm Infants (ELFIN).
Journal article
The ELFIN Trial Investigators Group None., (2018), Neonatology, 114, 142 - 148
-
Moderate hypothermia within 6 h of birth plus inhaled xenon versus moderate hypothermia alone after birth asphyxia (TOBY-Xe): a proof-of-concept, open-label, randomised controlled trial.
Journal article
Azzopardi D. et al, (2016), Lancet Neurol, 15, 145 - 153
-
Anticonvulsant effect of xenon on neonatal asphyxial seizures.
Journal article
Azzopardi D. et al, (2013), Arch Dis Child Fetal Neonatal Ed, 98, F437 - F439